Mineralys Therapeutics, Inc. Expected to Earn FY2024 Earnings of ($2.04) Per Share (NASDAQ:MLYS)

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at Lifesci Capital issued their FY2024 EPS estimates for Mineralys Therapeutics in a report issued on Tuesday, March 26th. Lifesci Capital analyst R. Katkhuda forecasts that the company will earn ($2.04) per share for the year. Lifesci Capital has a “Outperform” rating on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($2.64) per share.

Mineralys Therapeutics Stock Performance

NASDAQ:MLYS opened at $12.78 on Thursday. The stock’s 50 day moving average price is $13.17 and its 200 day moving average price is $10.10. Mineralys Therapeutics has a 52 week low of $5.85 and a 52 week high of $17.70. The company has a market capitalization of $634.27 million and a P/E ratio of -6.39.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.24.

Insider Buying and Selling

In related news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the stock in a transaction on Monday, February 12th. The shares were bought at an average price of $13.50 per share, for a total transaction of $7,499,992.50. Following the completion of the acquisition, the insider now directly owns 5,074,916 shares in the company, valued at approximately $68,511,366. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MLYS. CWM LLC acquired a new stake in shares of Mineralys Therapeutics in the third quarter worth $25,000. PNC Financial Services Group Inc. lifted its position in Mineralys Therapeutics by 17,821.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock worth $35,000 after purchasing an additional 4,099 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Mineralys Therapeutics in the fourth quarter worth $41,000. New York State Common Retirement Fund bought a new position in Mineralys Therapeutics in the first quarter worth $53,000. Finally, California State Teachers Retirement System bought a new position in Mineralys Therapeutics in the first quarter worth $70,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.